ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
US Tech 100
17,446.00
2.17%
Dow Jones
38,675.68
1.18%
Brent Oil
82.765
0.00%
Bitcoin
63,595.69
1.12%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU

  6. Acticor Biotech (ALACT) Quote

Acticor Biotech

Acticor Biotech (ALACT)

EU
0.384
0.014
(3.78%)
Closed May 04 11:30AM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.384
Bid
0.381
Ask
0.395
Volume
54,163
0.38 Day's Range 0.404
0.27 52 Week Range 6.22
Market Cap
5.012M
Previous Close
0.37
Open
0.389
Last Trade
312
@
0.384
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
76,362
Shares Outstanding
13,189,141
Dividend Yield
-
PE Ratio
-0.32
Earnings Per Share (EPS)
-1.2
Revenue
2.7M
Net Profit
-15.88M

About Acticor Biotech

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.acticor-biotech.com
Headquarters
Paris, Paris, Fra
Founded
1970
Acticor Biotech is listed in the Pharmaceutical Preparations sector of the Euronext with ticker ALACT. The last closing price for Acticor Biotech was 0.37 €. Over the last year, Acticor Biotech shares have traded in a share price range of 0.27 € to 6.22 €.

Acticor Biotech currently has 13,189,141 shares outstanding. The market capitalization of Acticor Biotech is 5.01 € million. Acticor Biotech has a price to earnings ratio (PE ratio) of -0.32.

ALACT Latest News

More News

ACTICOR BIOTECH : Report de la publication des résultats annuels et du Document d’enregistrement universel 2023

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 – ALACT), entreprise biopharmaceutique au stade clinique qui développe glenzocimab, un médicament innovant pour le traitement des urgences...

April 30 2024
Business Wire

ACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment

Analysis of the primary and secondary endpoints of the phase 2/3 ACTISAVE study showed no improved efficacy with glenzocimab Key results from this study will be presented at ESOC on May 15...

April 25 2024
Business Wire

Acticor Biotech will Present the Clinical Results of Its Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024

Results of ACTISAVE phase 2/3 clinical study in stroke expected in Q2 2024 Presentation of results during ESOC from 15 to 17 May 2024 Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 –...

April 15 2024
Business Wire

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of March 31, 2024

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular...

April 05 2024
Business Wire

ACTICOR BIOTECH : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 29 février 2024

Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers Regulatory News: ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT) (Paris:ALACT), société biopharmaceutique au stade clinique...

March 18 2024
Business Wire

Acticor Biotech réalise avec succès une augmentation de capital d’un montant total de 8 millions d'euros

Regulatory News: Ne pas diffuser, publier ou distribuer, directement ou indirectement, aux Etats-Unis d'Amérique, au Canada, en Australie ou au Japon. Ce communiqué de presse ne constitue pas un...

March 15 2024
Business Wire

Acticor Biotech lance une augmentation de capital de 7 M€ au minimum

Augmentation de capital composée d’une offre à des investisseurs qualifiés, à des catégories d’investisseurs, ainsi qu’aux investisseurs individuels via la plateforme PrimaryBid Engagements de...

March 14 2024
Business Wire

The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attack

University of Birmingham and Acticor Biotech News ReleaseLimited clinical access available The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first...

February 07 2024
GlobeNewswire Inc.

Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke

Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke    438 patients with stroke have been randomized in ACTISAVE study evaluating glenzocimab, in...

November 07 2023
GlobeNewswire Inc.

Acticor adapts its ACTISAVE clinical study to prepare the registration of glenzocimab for the treatment of stroke

ACTICOR adapts its ACTISAVE clinical study to prepare the registration of glenzocimab for the treatment of stroke Clinical results from ACTISAVE phase 2/3 study now expected in the second quarter...

September 14 2023
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.08930.16949152540.2950.670.2765895390.35455759DE
4-3.066-88.86956521743.454.210.271781910.55316225DE
12-4.016-91.27272727274.45.30.27763621.18637657DE
26-3.346-89.70509383383.735.320.27410151.5697593DE
52-4.916-92.75471698115.36.220.27207111.72157542DE
156-0.684-64.04494382021.068110.27316322.61863253DE
2600.0041.052631578950.38110.11645031.18995525DE

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BENFBeneficient
$ 6.8001
(254.17%)
31.01M
SGBXSafe and Green Holdings Corporation
$ 5.49
(87.37%)
92.18M
SHOTWSafety Shot Inc
$ 0.45
(45.16%)
644
AIPArteris Inc
$ 8.185
(38.03%)
1.11M
RGFReal Good Food Company Inc
$ 0.85
(37.32%)
4.26M
MNDRMobile health Network Solutions
$ 3.33
(-84.91%)
18.76M
NUVOHoldco Nuvo Group DG Ltd
$ 2.00
(-57.54%)
1.04M
SPTSprout Social Inc
$ 28.82
(-40.15%)
13.47M
UNITUniti Group Inc
$ 4.441
(-26.35%)
21.07M
IPDNProfessional Diversity Network Inc
$ 1.29
(-24.12%)
662.59k
AAPLApple Inc
$ 183.38
(5.98%)
163.22M
SQQQProShares UltraPro Short QQQ
$ 11.08
(-5.94%)
154.59M
JAGXJaguar Health Inc
$ 0.3164
(7.91%)
142.47M
NKLANikola Corporation
$ 0.6526
(6.55%)
106.88M
SGBXSafe and Green Holdings Corporation
$ 5.49
(87.37%)
92.18M

Discussion

View Full Feed
bbotcs bbotcs 4 minutes ago
lj: GRRR
Great post. U covered the spectrum.
My response: Show us the money! I wonder whether the company is supporting the share price to keep it above $5?
GRRR
sylvia07 sylvia07 6 minutes ago
Same here, Stock Barber!
DBMM
jimr1717 jimr1717 6 minutes ago
Citadel tops the list of hedge funds that have had the biggest profits since launch, with about $74 billion in net gains, according to estimates by LCH Investments.

https://www.bloomberg.com/news/articles/2023-01-05/ken-griffin-s-citadel-securities-posts-record-revenue-hedge-fund-sur
IFUS
TurboBuccaneer11 TurboBuccaneer11 7 minutes ago
Will be back to 0.050 end of next week.
CEOS
Real McCoy Real McCoy 7 minutes ago
That’s all I’m interested in discussing.

I don’t care about your bitter frustration.

Someone who is actively calling someone they are responding to a bot, meaning they actively think they are not talking to anyone, is dumber and more desperate than just the “out 100%”
Alexulf Alexulf 7 minutes ago
Earnings Report Comes On Monday - PlantX, there will be an estimated 34 % move up on the trading day; that is if we believe one of the technical chart forecast. Me, I believe it can move a lot more, of course depending on the earnings report result. Have a good weekend
https://investorshub.a
UpTickMeA$AP UpTickMeA$AP 8 minutes ago
It's hard to come up with a name, when attempting to spin a truth that doesn't exist. Giving the name, in itself, opens the nonsense up to be destroyed with truth.

The many spins over the years, have left very few that even sound doable.

Even the Arizona clown car LLC
COOP
gfp927z gfp927z 8 minutes ago
H5N1 - the next pandemic?


>>> What a US farmworker’s case of bird flu tells us about tracking the infection


CNN

by Brenda Goodman

5-3-24


https://www.msn.com/en-us/health/other/what-a-us-farmworker-s
nobody9 nobody9 8 minutes ago
Hmmm, I didn't know they were gonna sell bedpans now, should have loaded the boat yesterday, gonna mortgage my house now and go all-in on Monday, not even scale in, straight up market-buy order for my net worth, whoohoo, bedpans!
ENZC
gfp927z gfp927z 9 minutes ago
H5N1 - the next pandemic?


>>> What a US farmworker’s case of bird flu tells us about tracking the infection


CNN

by Brenda Goodman

5-3-24


https://www.msn.com/en-us/health/other/what-a-us-farmworker-s
FooBarAndGrill FooBarAndGrill 10 minutes ago
Langley is Contracting $41M with $LUNR for the following:
Deployable Hopper for Extreme Lunar Surface Access. Develop and demonstrate a small robotic hopper, deployed as a secondary payload from the Nova-C lander, that can provide access to extreme environments and locations of interest on t
LUNR
Smattchew Smattchew 10 minutes ago
I already said that $bioaq is dead, you can't read. Why are you trying to tell me so? Reading is hard work. Another check mark in the "benefit in some manner from chosing to ignore" category and for the learning disability category.
BIOAQ
VVVVVV VVVVVV 11 minutes ago
It’s quoted…” I used to love sharing what I would dig up….no more “.

Are you freaking kidding me, right now? What in the world have you ever contributed, besides disrespecting and bashing every shareholder that doesn’t agree with your opinion (s). You call and harass them, disresp
VPLM
awesomed007 awesomed007 11 minutes ago
What current pps target looking at? .25 possible?😉🫢🏄‍♂️
SPZI
I_luv_cydy I_luv_cydy 12 minutes ago
Hey DJ - why so condescending? Why call someone a moron like that? If that person wants to spend his money buying ‘leronlimab stocks’ why do you REALLY care at all? Why not let people spend their own money the way they want to. ?? Do we tell you how to invest ?
Curious why such anger?
CYDY
Double DD Double DD 13 minutes ago
Geez at least a few quarter sticks to get it going!!! Weeeeee igpk
IGPK
littlejohn littlejohn 13 minutes ago
GRRR $5ish, was almost $70 in July,2023

after announcing big Egypt contract...

https://www.barchart.com/stocks/quotes/GRRR/interactive-chart

https://finance.yahoo.com/news/gorilla-technology-signs-contract-deploy-210000935.html

Chit hitting
GRRR
tredenwater2 tredenwater2 14 minutes ago
“ And that the belief by the general market is very low.”

Typically the “belief” by the general market or another way is the “fair and balanced” market does not come into play until institutional ownership reaches 60% or OS shares. Good luck with waiting until that happens to give cr
AVXL
lesgetrich lesgetrich 15 minutes ago
C:\Users\lesme\Dropbox\Personal\Private\Documents\Ihub Pics\Political2\Biden\Christian18.jpg
MasterBlastr MasterBlastr 15 minutes ago
Heading out for a few hours, anxious to see that will transpire.
awesomed007 awesomed007 15 minutes ago
Didn’t dbmm come off ce? Now pink current. Point being, we know what’s coming for cybl 🤞👍

https://stkt.co/30y7tF1S
CYBL
hookrider hookrider 15 minutes ago
rooster: LOL, with Bid Joe when he says 3 words in a row we know what he is talking about. We can eat a hamburger and drink a coke and have it stolen.
velcro velcro 15 minutes ago
Creative Realities is doing so well. Would not be surprised if there is another buyout offer.
CREX
Mutat Mutat 15 minutes ago
Chandra said.

All the licenses and IPs had been terminated with immediate effect as per my termination letter on 10th April 2024. Please focus on bedpans and other uncomplicated medical devices to add shareholder value.
ENZC

Your Recent History

EU
ALACT
Acticor Biotech
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved